{"id":"arthemeter-lumefantrin","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL38827","moleculeType":"Small molecule","molecularWeight":"528.95"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Artemether is a fast-acting antimalarial agent that targets the parasite's 80S ribosome, while lumefantrin is a slow-acting agent that targets the parasite's heme detoxification pathway. The combination of these two drugs provides a synergistic effect, making it effective against a wide range of Plasmodium species.","oneSentence":"Artemether-lumefantrin is a combination antimalarial drug that works by inhibiting the growth and replication of Plasmodium parasites.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:35.668Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of uncomplicated malaria caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae"}]},"trialDetails":[{"nctId":"NCT01054248","phase":"PHASE3","title":"Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-02-16","conditions":"Malaria","enrollment":511}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Coartem"],"phase":"phase_3","status":"active","brandName":"arthemeter-lumefantrin","genericName":"arthemeter-lumefantrin","companyName":"University of Oxford","companyId":"university-of-oxford","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Arthemeter-lumefantrin is a small molecule that inhibits Ferriprotoporphyrin IX, a mechanism consistent with its classification as an inhibitor. It has been studied as a treatment for malaria in clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}